STOCK TITAN

Roche Holding AG - RHHBY STOCK NEWS

Welcome to our dedicated news page for Roche Holding (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Roche Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Roche Holding's position in the market.

Rhea-AI Summary
Roche has announced the extension of its cobas® connection modules (CCM) sample conveyors system with the newly developed CCM Vertical, allowing transportation of samples on overhead conveyors. This modular and flexible solution optimizes laboratory space and enables the transport of samples to adjacent floors or rooms, addressing the space limitations in laboratories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
none
-
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
none
Rhea-AI Summary
Roche Group reports strong sales growth in Pharmaceuticals Division and decline in Diagnostics Division due to lower demand for COVID-19 tests. Core earnings per share and IFRS net income decrease. Important pipeline milestones reached. Outlook for 2023 confirmed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
covid-19
-
Rhea-AI Summary
Roche has announced a partnership with Alnylam to develop and commercialize zilebesiran, an investigational RNAi therapeutic for the treatment of hypertension. Hypertension affects over 1.2 billion adults worldwide and is a leading cause of cardiovascular disease. Zilebesiran has the potential to be a best-in-disease treatment, with positive Phase 1 data showing dose-dependent reductions in blood pressure. The partnership will allow both companies to pursue joint development and commercialization, with Roche obtaining exclusive commercialization rights outside the US. Alnylam will receive an upfront payment of $310 million and will share costs and profits equally with Roche in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
none
-
Rhea-AI Summary
Genentech, a member of the Roche Group, will present data on its ophthalmology portfolio, including Vabysmo, at the 2023 ASRS Annual Meeting. The data highlight the efficacy of Vabysmo in treating wet AMD and DME, with positive anatomical outcomes and real-world evidence supporting its use. Vabysmo is currently approved in over 70 countries and has distributed over one million doses globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
clinical trial
Roche Holding AG

OTC:RHHBY

RHHBY Rankings

RHHBY Stock Data

205.51B
727.48M
0.16%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Switzerland
Basel